Form 4: Zymeworks EVP Paul Schneider Receives Equity Grant

Zymeworks Inc. EVP and General Counsel Paul R. Schneider was granted 178,000 stock options and 119,000 restricted stock units.

Summary

• Paul R. Schneider, EVP and General Counsel of Zymeworks Inc., received a new equity compensation package on May 13, 2026.
• The grant includes 178,000 stock options with an exercise price of $24.57 per share.
• The grant also includes 119,000 restricted stock units (RSUs), each representing a contingent right to one share of common stock.
• Stock options vest over four years, with 25% vesting on the first anniversary and the remainder in 36 equal monthly installments.
• RSUs vest in four equal annual installments beginning on the first anniversary of the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding executive compensation with no immediate impact on the company's operational or financial trajectory.

Positives

• Equity-based compensation aligns the interests of the General Counsel with long-term shareholder value.
• The multi-year vesting schedule encourages executive retention.

Negatives

• The issuance of new equity awards results in potential dilution for existing shareholders.

Risks

• Future share price volatility may impact the ultimate value realized by the executive from these grants.
• The company remains subject to market risks inherent in the biotechnology sector.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a disclosure of executive compensation.

Industry Context

StockSavvy.ai notes that equity grants for C-suite executives in the biotechnology sector are standard practice for talent retention and performance alignment, particularly for companies in the clinical development stage.

Comparison to Industry Standards

• The use of a four-year vesting schedule for both options and RSUs is consistent with standard corporate governance practices for U.S. public companies.
• The mix of options and RSUs is a common compensation structure used to balance risk-taking incentives with retention.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise and vesting of these equity awards.

Next Steps

• Vesting of 25% of stock options on May 13, 2027.
• Vesting of the first annual installment of RSUs on May 13, 2027.

Key Dates

Keywords

Zymeworks, ZYME, Form 4, Insider Trading, Equity Compensation, Biotech